Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by low platelet counts, leading to easy bruising and bleeding. It accounts for a significant portion of hematological autoimmune conditions globally. As per Mohamed Amine Bekadja et al., 2024, the annual incidence of ITP is estimated at 1.9–6.4 per 100,000 children and 3.3 per 100,000 adults. The idiopathic thrombocytopenic purpura therapeutics market is expanding with a growing focus on targeted therapies and novel biologics. According to the idiopathic thrombocytopenic purpura pipeline analysis by Expert Market Research, this treatment pipeline is expected to witness considerable growth in the coming years.
Major companies involved in the idiopathic thrombocytopenic purpura pipeline analysis include Pfizer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and others.
Leading drugs currently in the pipeline include TQB3473, CM313, HMPL-523, and others.
Strong pipeline growth for idiopathic thrombocytopenic purpura is driven by increasing clinical trials for thrombopoietin receptor agonists and rising R&D investments in novel monoclonal antibodies and immune-modulating therapies.
The Idiopathic Thrombocytopenic Purpura Pipeline Analysis Report by Expert Market Research gives comprehensive insights into idiopathic thrombocytopenic purpura therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for idiopathic thrombocytopenic purpura. The idiopathic thrombocytopenic purpura report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The idiopathic thrombocytopenic purpura pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with idiopathic thrombocytopenic purpura treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to idiopathic thrombocytopenic purpura.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Idiopathic thrombocytopenic purpura (ITP), also known as immune thrombocytopenia, is an autoimmune disorder where the immune system mistakenly targets and destroys platelets. It typically occurs when autoantibodies bind to platelet membrane proteins, leading to their premature destruction and reduced production in the bone marrow. Although the exact cause remains unknown, it is believed to involve a complex interplay of immune dysregulation. ITP can be acute or chronic and affects both children and adults, often presenting with symptoms like easy bruising, petechiae, and prolonged bleeding.
Idiopathic thrombocytopenic purpura treatment includes corticosteroids, intravenous immunoglobulin, or rituximab in resistant cases, aiming to increase platelet count and prevent severe bleeding. In November 2024, Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. received regulatory approval in Japan for Rituxan® (rituximab) as an additional treatment for chronic idiopathic thrombocytopenic purpura in children, expanding its prior use approved only for adults.
Idiopathic thrombocytopenic purpura (ITP) demonstrates a variable incidence across age groups and regions. According to Mohamed Amine Bekadja et al., 2024, the annual incidence is estimated at 1.9-6.4 per 100,000 in children and approximately 3.3 per 100,000 in adults. Epidemiological data from the United Kingdom, France, Taiwan, and Korea show a higher incidence among women (3.03–6.0 per 100,000 person-years) compared to men (2.3–4.5 per 100,000 person-years), with the highest rates observed in individuals aged 60 to 84 years.
This section of the report covers the analysis of idiopathic thrombocytopenic purpura drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total idiopathic thrombocytopenic purpura clinical trials at 48%, indicating strong mid-stage development. Phase III follows with 25%, reflecting promising advancements toward late-stage trials. Phase I accounts for 18%, and phase IV contributes 4%. This balanced progression highlights robust innovation, boosting future growth for the pipeline.
The drug molecule categories covered under the idiopathic thrombocytopenic purpura pipeline analysis include small molecules, monoclonal antibodies, recombinant proteins, RNA-based therapeutics, and cell therapies. The idiopathic thrombocytopenic purpura report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for idiopathic thrombocytopenic purpura. Bruton tyrosine kinase inhibitors are emerging as promising therapeutic agents in the treatment of idiopathic thrombocytopenic purpura. For instance, rilzabrutinib, an oral, reversible BTK inhibitor, demonstrated a durable platelet response in the phase 3 LUNA 3 trial. It works by targeting immune-mediated pathways, reducing autoantibody production and macrophage-driven platelet destruction in ITP patients.
The EMR report for the idiopathic thrombocytopenic purpura pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed idiopathic thrombocytopenic purpura therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in idiopathic thrombocytopenic purpura clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for idiopathic thrombocytopenic purpura. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of idiopathic thrombocytopenic purpura drug candidates.
TQB3473, developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety in treating adult patients with chronic immune thrombocytopenia (ITP). This oral Syk inhibitor is targeting B cell receptor and Fcγ receptor signaling pathways. The study is assessing whether TQB3473 significantly improves sustained platelet response compared to placebo in patients who have failed prior standard therapies.
CM313, sponsored by Keymed Biosciences Co. Ltd, is a humanized monoclonal anti-CD38 antibody currently being evaluated in a Phase 2 trial for primary immune thrombocytopenia (ITP). This randomized, double-blind study is assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection. The drug is targeting both short-lived and long-lived plasma cells, aiming to overcome resistance in ITP treatment. CM313 works by targeting CD38-expressing plasma cells, inducing cell death through Fc-receptor–dependent mechanisms, potentially reducing autoantibody production and improving platelet counts in ITP patients.
HMPL-523, sponsored by Hutchmed, is an oral agent that reversibly inhibits Syk, thereby preventing the destruction of opsonized platelets and auto-antibody formation. It is currently being evaluated in a Phase 1 trial to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in adults with primary ITP. Though still under development, HMPL-523 has shown promise in previous studies and may serve as an alternative to fostamatinib for Syk inhibition.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Idiopathic Thrombocytopenic Purpura Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for idiopathic thrombocytopenic purpura. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into idiopathic thrombocytopenic purpura collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share